Skip to main content
SpringerLink
Log in

Progress in the Development of Epstein-Barr Virus Vaccines

  • Chapter
New Generation Vaccines

Part of the book series: NATO ASI Series ((NSSA,volume 261))

  • 61 Accesses

Abstract

Epstein-Barr virus (EBV) is one of the small number of human herpesviruses (reviewed by Kieff and Liebowitz, 1990; Miller, 1990). These are complex viruses with large double-stranded DNA genomes, the EBV gene being approximately 170 Kd and coding for at least 70 genes. A prominent characteristic of these viruses in this group is that they are able to persist in a latent infectious state in humans in the face of sustained and comprehensive immune response which include virus-neutralising antibodies in the sera of infected individuals. EBV infects greater than 90% of the human population world-wide, infection usually occurring early in childhood, but in the Western world infection is frequently delayed until adolescence when there is a 50% chance of infectious mononucleosis occurring. EBV can infect only B lymphocytes and certain classes of epithelial cell by binding to the complement receptor CR2 of B lymphocytes and a similar molecule on epithelial cells (Hutt-Fletcher, 1991). The mode of infection is by horizontal transmission through an oral portal of entry leading to infection of epithelial cells in the oropharynx. It is here that the virus is able to reside in a state of productive infection generating infectious virus in the saliva which can infect other individuals. B lymphocytes in the circulation passing in the region of these infected epithelial cells become infected also but only a very small number ever progress to productive infection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Beisel, C., Tanner, J., Matsuo, T., Thorley-Lawson, D., Kedy, F. and Kieff, E., 1985, Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene, J. Virol., 54:665.

    PubMed  CAS  Google Scholar 

  • Bejarano, M. T., Masucci, M. G., Morgan, A., Morein, B., Klein, G. and Klein, E., 1990, Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation, J. Virol., 64:1398.

    PubMed  CAS  Google Scholar 

  • Byars, N. E. and Allison, A. C., 1987, Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity, Vaccine, 5:223.

    Article  PubMed  CAS  Google Scholar 

  • Byars, N. E., Nakaon, G., Welch, M., Lehman, D. and Allison, A. C., 1991, Improvement of hepatitis B vaccine by the use of a new adjuvant, Vaccine, 9:309.

    Article  PubMed  CAS  Google Scholar 

  • Chen, C. J., Liang, K. Y., Chang, Y. S., Wang, Y. F., Hsieh, T., Hsu, M., Chen, J. Y. and Liu, M. Y., 1990, Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency, Anticancer Res., 10:547.

    PubMed  CAS  Google Scholar 

  • Cleary, M. L., Epstein, M. A., Finerty, S., Dorfman, R. F., Bornkamm, G. W., Kirkwood, J. K, Morgan, A. J. and Sklar, J., 1985, Individual tumors of multifocal EBV-induced malignant lymphomas in tamarins arise from different B-cell clones, Science, 228:722.

    Article  PubMed  CAS  Google Scholar 

  • David, E. M. and Morgan, A. J., 1988, Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography, J. Immunol. Methods, 108:231.

    Article  PubMed  CAS  Google Scholar 

  • Dillon, S. B., Demuth, S. G., Schneider, M. A., Weston, C. B., Jones, C. S., Young, J. F., Scott, M., Bhatnaghar, P. K., LoCastro, S. and Hanna, N., 1992, Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant, Vaccine, 10:309.

    Article  PubMed  CAS  Google Scholar 

  • Emini, E. A., Schleif, W. A., Armstrong, M. E., Silberklang, M., Schultz, L. D., Lehman, D., Maigetter, R. Z., Qualtiere, L. F., Pearson, G. R. and Ellis, R. W., 1988, Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine, Virology, 166:387.

    Article  PubMed  CAS  Google Scholar 

  • Emini, E. A., Schleif, W. A., Silbeklang, M., Lehmanm, D. and Ellis, R. W., 1989, Vero cell-expressed Epstein-Barr virus D. gp350/220 protects marmosets from EBV challenge, J. Med. Virol, 27:120.

    Article  PubMed  CAS  Google Scholar 

  • Epstein, M. A., 1976, Epstein-Barr virus - is it time to develop a vaccine program? Journal of the National Cancer Institute, 56:697.

    PubMed  CAS  Google Scholar 

  • Epstein, M. A., Achong, B. G. and Barr, Y. M., 1964, Virus particles in cultured lymphoblasts from Burkitt’s lymphoma, Lancet, i:703.

    Google Scholar 

  • Epstein, M. A., Morgan, A. J., Finerty, S., Randle, B. J. and Kirkwood, J. K., 1985, Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine, Nature, 318:287.

    Article  PubMed  CAS  Google Scholar 

  • Epstein, M. A., North, J. R. and Morgan, A. J., 1983, Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form, J. Gen. Virol., 64:455.

    Article  PubMed  Google Scholar 

  • Epstein, M. A., Randle, B. J., Finerty, S. and Kirkwood, J. K., 1986, Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals, Clin. Exp. Immunol., 63:485.

    PubMed  CAS  Google Scholar 

  • Epstein, M. A., zur Hausen, H., Ball, G. and Rabin, H., 1975, Pilot experiments with EBV in owl monkeys (Aotus trivirgatus). III: Serological and biochemical findings in an animal with reticuloproliferative disease, Int. J. Cancer, 15:17.

    Article  PubMed  CAS  Google Scholar 

  • Facer, C. A. and Playfair, J. H., 1989, Malaria, Epstein-Barr virus, and the genesis of lymphomas, Adv. Cancer Res., 53:33.

    Article  PubMed  CAS  Google Scholar 

  • Finerty, S., Tarlton, J., Mackett, M., Conway, M., Arrand, J. R., Watkins, P. E. and Morgan, A. J., 1992, Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector, J. Gen. Virol, 743:449.

    Article  Google Scholar 

  • Haddad, R. S. and Hutt-Fletcher, L. M., 1989, Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells, J. Virol., 63:4998.

    PubMed  CAS  Google Scholar 

  • Hutt-Fletcher, L., 1991, Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis, Springer Seminars in Immunopathology 13:117.

    Article  PubMed  CAS  Google Scholar 

  • Kaaden, O. R. and Dietzschold, B. 1974, Alterations of the immunological specificity of plasma membranes of cells infected with Marek’s disease and turkey herpesviruses, J. Gen. Virol., 25:1.

    Article  PubMed  CAS  Google Scholar 

  • Kieff, E. and Liebowitz, D., 1990, Epstein-Barr virus and tis replication, in: “Virology,” B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. O. Melnick, T. P. Month and B. Roizman, eds., Raven Press, New York.

    Google Scholar 

  • Laufs, R. and Steinke, H., 1975, Vaccination of non-human primates against malignant lymphoma, Nature, 253:71.

    Article  PubMed  CAS  Google Scholar 

  • Lu, S., Day, N. E., Degos, L., Lepage, V., Wang, P-C., Chan, S-H., Simons, M., McKnight, B., Easton, D., Zeng, Yi and de-The, G., 1991, Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region, Nature, 346:470.

    Article  Google Scholar 

  • Madej, M., Conway, M. J., Morgan, A. J., Sweet, J., Wallace, L., Arrand, J. and Mackett, M., 1992, Purification and characterisation of Epstein-Barr virus gp340/220 produced by a bovine papilloma virus vector system, Vaccine, 10:777.

    Article  PubMed  CAS  Google Scholar 

  • Magrath, I., 1990, The pathogenesis of Burkitt’s lymphoma, Adv. Cancer Res., 55:133–270.

    Article  PubMed  CAS  Google Scholar 

  • Miller, G., 1990, Epstein-Barr virus, in: “Virology,” B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. O. Melnick, T. P. Month and B. Roizman, eds., Raven Press, New York.

    Google Scholar 

  • Morein, B., Fossum, C., Lovgren, K. and Hoglund, S., 1990, The Iscom - a modern approach to vaccines, Seminars in Virology, 1:49.

    Google Scholar 

  • Morgan, A. J., Allison, A. C., Finerty, S., Scullion, F. T., Byars, N. E. and Epstein, M. A., 1989, Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use, J. Med. Virol., 29:74.

    Article  PubMed  CAS  Google Scholar 

  • Morgan, A. J., Finerty, S., Lovgren, K., Scullion, F. T. and Morein, B., 1988, Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EBV envelope glycoprotein gp340 incorporated into immune-stimulating complexes, J. Gen. Virol., 69:2093.

    Article  PubMed  CAS  Google Scholar 

  • Morgan, A. J., Mackett, M., Finerty, S., Arrand, J. R., Scullion, F. T. and Epstein, M. A., 1988, Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins aginst EBV-induced malignant lymphomas, J. Med. Virol., 25:189.

    Article  PubMed  CAS  Google Scholar 

  • Morgan, A. J., North, J. R. and Epstein, M. A., 1983, Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form, J. Gen. Virol., 64:455.

    Article  PubMed  CAS  Google Scholar 

  • Morgan, A. J., Smith, A. R., Barker, R. N. and Epstein, M. A., 1984, A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340, J. Gen. Virol, 65:397.

    Article  PubMed  CAS  Google Scholar 

  • Moss, D. J., Misko, I. S., Sculley, T. B., Apolloni, A., Khanna, R. and Burrows, S. R., 1991, Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis, Springer Seminars in Immunopathology, 13:147.

    Article  PubMed  CAS  Google Scholar 

  • Motz, M., Deby, G. and Wolf, H., 1987, Truncated versions of the two major Epstein-Barr viral glycoproteins (gp250/350) are secreted by recombinant Chinese hamster ovary cells, Gene, 58:149.

    Article  PubMed  CAS  Google Scholar 

  • Mueller, N., Evans, A., Harris, N. L., Comstock, G. W., Jellum, E., Magnus, K., Orentriech, N., Polk, B. F. and Vogelman, J., 1989, Hodgkin’s disease and Epstein-Barr virus. altered antibody pattern before diagnosis, N. Engl. J. Med., 320:689.

    Article  PubMed  CAS  Google Scholar 

  • Nalesnik, M. A., 1991, Lymphoproliferative disease in organ transplant recipients, Springer Seminars in Immunopatholsogy, 13:181.

    Google Scholar 

  • O’Hagan, D. T., Rahman, D., McGee, J. P., Jeffry, H., Davies, M. C., Williams, P., Davis, S. S. and Challacombe, S. J., 1991, Biodegradable microparticles as controlled release antigen delivery systems, Immunology, 73:239.

    PubMed  Google Scholar 

  • Ooka, T., de Turenne-Tessier, M. and Stolzenberg, M. C., 1991, Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases, Springer Seminars in Immunopathology, 13:233.

    Article  PubMed  CAS  Google Scholar 

  • Pallesen, G., Hamilton Dutoit, S. J., Rowe, M. and Young, L. S., 1991, Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease, Lancet, 337:320.

    Article  PubMed  CAS  Google Scholar 

  • Parkin, D. M., Stjemsward, J. and Muri, C. S., 1984, Estimates for the worldwide frequency of twelve major cancers, Bulletin of the World Health Organisation, 62:163.

    CAS  Google Scholar 

  • Pither, R. J., Zhang, C. X., Shiels, C. Tarlton, J. Finerty, S. and Morgan, A. J., 1992a, Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340, J. Virol., 66:1246.

    CAS  Google Scholar 

  • Pither, R. J., Nolan, L., Tarlton, J., Walford, J. and Morgan, A. J., 1992b, Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera, J. Gen. Virol., 73:1409.

    Article  CAS  Google Scholar 

  • Purtilo, D. T., 1991, X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology, Springer Seminars in Immunopathology, 13:181.

    Article  PubMed  CAS  Google Scholar 

  • Ragot, T., Tosoni-Pittoni, E., Finerty, S., Morgan, A. J. and Perricaudet, M., 1991, Recombinant adenoviruses which express the Epstein-Barr virus membrane antigen gp340/220, gp220 only or a secreted form of gp340 induce persistent virus-neutralizing antibodies in rabbits in: “Epstein-Barr Virus and Human Disease,” D. V. Ablahsi, ed., Humana Press, Clifton, New Jersey.

    Google Scholar 

  • Ragot, T., Tosoni-Pittoni, E., de Mazancourt, S., Finerty, S., Morgan, A. J. and Perricaudent, M., 1992a, Recombinant adenoviruses which express the Epstein-Barr virus membrane antigen gp340/220 and used as a live vaccine induce persistent virus-neutralizing antibodies in rabbits, J. Gen. Virol., (submitted for publication).

    Google Scholar 

  • Ragot, T., Finerty, S., Watkins, P., Perricaudet, M. and Morgan, A. J., 1992b, Protective immunity against EBV lymphoma in the cottontop tamarin is induced by adenovirus recombinants expressing the EBV envelope glycoprotein gp340, J. Gen. Virol., 74:501.

    Article  Google Scholar 

  • Schultz, L. D., Tanner, J., Hofmann, K. J., Emini, E. A., Condra, J. H., Jones, R. E., Kieff, E. and Ellis, R. W., 1987, Expression and secretion in yeast of a 400-kDa envleope glycoprotein derived from Epstein-Barr virus, Gene, 54:113.

    Article  PubMed  CAS  Google Scholar 

  • Shope, T., Dechairo, D. and Miller, G., 1973, Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus, Proc. Natl. Acad. Sci. USA, 70:2487.

    Article  PubMed  CAS  Google Scholar 

  • Sixbey, J. W. and Yao, Q-Y., 1992, Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism, Science, 255:1578.

    Article  PubMed  CAS  Google Scholar 

  • Tanner, J., Whang, Y., Sample, J., Sears, A. and Kieff, E., 1988, Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes, J. Virol.,, 62:4452.

    PubMed  CAS  Google Scholar 

  • Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J-C., Cox, W. I., Davis, S. W., Vanderhoeven, J., Meignier, B., Riviere, M., Languet, B. and Paoletti, E., 1992, NYVAC: A highly attenuated strain of vaccinia virus, Virology, 88:217.

    Article  Google Scholar 

  • Taylor, J., Weinberg, R., Tartaglia, J., Richardson, C., Alkhatib, G., Briedis, D., Appel, M., Norton, E. and Papoletti, E., 1992, Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins, Virology, 187:321.

    Article  PubMed  CAS  Google Scholar 

  • Ulaeto, D., Wallace, L., Morgan, A. J., Morein, B. and Rickinson, A. B., 1988, In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T-cell clones specific for the major envelope glycoprotein, gp340, Eur. J. Immunol., 18:1689.

    Article  PubMed  CAS  Google Scholar 

  • Wallace, L. E., Wright, J., Ulaeto, D. O., Morgan, A. J. and Rickinson, A. B., 1991, Identification of CD4+ T cell epitopes of the candidate Epstein-Barr virus vaccine glycoprotein gp340, I. Virol., 65:3821.

    CAS  Google Scholar 

  • Watkins, D. I., Hodi, F. S. and Letvin, N. L., 1988, A primate species with a limited major histocompatability complex class I polymorphism, Proc. Natl. Acad. Sci. USA, 85:7714.

    Article  PubMed  CAS  Google Scholar 

  • Whang, Y., Silberklang, M., Morgan, A., Munshi, S., Lenny, A. B., Ellis, R. W. and Kieff, E., 1987, Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells, J. Virol., 61:1796.

    PubMed  CAS  Google Scholar 

  • Young, L. S., Finerty, S., Rickinson, A. B. and Morgan, A. J., 1988, Epstein-Barr virus gene expression in lymphomas induced by the virus in the cottontop tamarin, J. Virol., 63:1967.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology & Microbiology, University of Bristol Medical School, Bristol, BS8 1TD, UK

    Andrew J. Morgan

Authors
  1. Andrew J. Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Pharmacy, University of London, London, UK

    Gregory Gregoriadis  & Brenda McCormack  & 

  2. Syntex Research, Palo Alto, California, USA

    Anthony C. Allison

  3. SmithKline Beecham Pharmaceuticals, Surrey, UK

    George Poste

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Morgan, A.J. (1993). Progress in the Development of Epstein-Barr Virus Vaccines. In: Gregoriadis, G., McCormack, B., Allison, A.C., Poste, G. (eds) New Generation Vaccines. NATO ASI Series, vol 261. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2948-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2948-4_17

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6281-4

  • Online ISBN: 978-1-4615-2948-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation